PDCD1 and head and neck squamous cell carcinoma: Additionally, the immune-checkpoint PD-1 inhibitor, Pembrolizumab, is approved for recurrent or metastatic HNSCC; and the HPV vaccine has been shown to decrease the incidence of HPV-associated oropharyngeal cancers [16,17].